BOC International Raises TIGERMED (03347) Target Price to HK$51, Maintains "BUY" Rating
Stock News
Sep 03
BOC International released a research report stating that TIGERMED's (03347) first-half performance reflects the ongoing challenges facing China's biotechnology industry, where weak demand and financing constraints have impacted project volumes and pricing. While profitability has contracted, overseas business expansion has helped mitigate some of the adverse effects. Looking ahead, a recovery in domestic financing and new overseas orders may support gradual performance improvement, though the timing remains uncertain. The firm maintains a "BUY" rating on the stock with a target price raised from HK$40 to HK$51.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.